Results 221 to 230 of about 1,178,585 (315)

Correction to ‘Natriuretic peptides and C‐reactive protein in in heart failure and malnutrition: A systematic review and meta‐analysis’

ESC Heart Failure, Volume 12, Issue 2, Page 1524-1524, April 2025.
wiley   +1 more source

Cardiovascular toxicity from immune checkpoint inhibitor therapy: an inflammatory continuum

British Journal of Pharmacology, EarlyView.
Immune checkpoint inhibitor (ICI) therapy has markedly improved outcomes in advanced malignancies but has also revealed a distinct spectrum of cardiovascular immune‐related adverse events. Myocarditis represents the most severe manifestation, while non‐inflammatory left ventricular dysfunction and vascular inflammation have emerged as additional ...
Fabrice Reyes, Florian Buehning, Tobias Lerchner, Julia Vogel, Raluca I. Mincu, Matthias Totzeck, Tienush Rassaf, Lars Michel   +7 more
wiley   +1 more source

Prognostic implications of N-terminal pro-B-type natriuretic peptide in patients undergoing transcatheter aortic valve implantation. [PDF]

Eur Heart J Open
Salerno N, Leo I, Canino G, Bellantoni A, Di Costanzo A, Comito F, Mazza GA, Panuccio G, Giordano S, De Rosa S, Torella D, Sorrentino S.   +11 more
europepmc   +1 more source

Arrhythmias associated with immune checkpoint inhibitor therapy—A clinical perspective

British Journal of Pharmacology, EarlyView.
Immune checkpoint inhibitors (ICIs) have transformed cancer therapy but are associated with a growing spectrum of cardiovascular immune‐related adverse events. Among these, arrhythmias represent a rare yet potentially life‐threatening complication. ICI‐induced arrhythmias encompass a wide clinical spectrum, including atrial arrhythmias, conduction ...
Dong Wang, Melanie Ricke‐Hoch, David Duncker, Johann Bauersachs, Dominik Berliner   +4 more
wiley   +1 more source

Carboxy-terminal 24-amino-acid peptide of integral membrane protein 2A is produced in the heart and stimulates atrial natriuretic peptide release. [PDF]

Sci Rep
Osaki T, Mochiduki A, Nishigori M, Shinmura K, Miyazaki T, Mishiro-Sato E, Kadonosono T, Tamaki K, Okumura N, Takao T, Sasaki K, Minamino N.   +11 more
europepmc   +1 more source

sGC stimulator BAY 41‐8543 improves survival and ventricular function in a rat model of doxorubicin‐induced cardiomyopathy with nephrotic syndrome

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Anthracyclines such as doxorubicin (DOXO) remain a cornerstone of cancer therapy but are associated with a high risk of cardiotoxicity and subsequent heart failure (HF). Impairment of NO/soluble guanylyl cyclase (sGC)/cGMP pathway has been reported in anthracycline‐induced cardiomyopathy.
Olga Gawrys, Petra Škaroupková, Soňa Kikerlová, Zdeňka Vaňourková, Martina Hüttl, Olga Lenčová, Kasin Yadunandam Anandam, Svenja Stomberg, Sönke Behrends, Barbara Szeiffová Bačová, Matúš Sykora, Lisa Dietz, Peter Sandner, Luděk Červenka, Martin Štěrba   +14 more
wiley   +1 more source

Analytical Validation of a Novel Point-Of-Care Quantitative Immunoassay for Feline N-Terminal Pro-Brain Natriuretic Peptide. [PDF]

Vet Clin Pathol
Javery EA, Fries RC, Kadotani S, Kruckman L, Humphries L, Prabhakar SR, Rosser MF.   +6 more
europepmc   +1 more source

Heart failure medication to prevent cancer therapy–related cardiac dysfunction: A narrative review

British Journal of Pharmacology, EarlyView.
Advances in oncological therapies have improved cancer survival but also have increased the clinical incidence of cancer therapy–related cardiac dysfunction (CTRCD), a spectrum of conditions ranging from subclinical biomarker or strain abnormalities to progressive heart failure and cardiogenic shock.
Fabian Voß, Paul Goerke, Malte Kelm, Amin Polzin   +3 more
wiley   +1 more source

Association Between Locomotive Syndrome and N-Terminal Pro B-Type Natriuretic Peptide Concentration in a Health Screening Cohort: A Retrospective Cross-Sectional Study. [PDF]

Circ Rep
Mizuno C, Hiraiwa H, Yokoyama S, Ito T, Sahara K, Honda T, Tanaka T, Kojima T, Kariya N, Ito R, Kazama S, Kondo T, Morimoto R, Kawashima H, Murohara T.   +14 more
europepmc   +1 more source

Bruton tyrosine kinase inhibitors and cardiovascular adverse events

British Journal of Pharmacology, EarlyView.
Abstract Bruton tyrosine kinase inhibitors (BTKi) have transformed the management of chronic lymphocytic leukaemia and other B‐cell malignancies, yet their therapeutic benefit is tempered by clinically relevant cardiovascular toxicities (predominantly atrial fibrillation, hypertension, bleeding and ventricular arrhythmias).
Massimiliano Camilli, Cristina Madaudo, Emanuela Salvatorelli, Giorgio Minotti, Pierantonio Menna   +4 more
wiley   +1 more source